G92.05 Immune effector cell-associated neurotoxicity syndrome, grade 5

Name of the Condition

• Immune effector cell-associated neurotoxicity syndrome, grade 5

Summary

Immune effector cell-associated neurotoxicity syndrome (ICANS) is a neurological condition that can occur following treatment with certain immunotherapies, particularly those involving immune effector cells like CAR T-cells. It is characterized by a range of neurologic symptoms resulting from inflammation or toxicity to the central nervous system. The "grade 5" designation indicates life-threatening severity, often requiring intensive medical intervention.

Causes

ICANS is caused by the release of inflammatory cytokines and immune-mediated damage to the brain and nervous system, typically triggered by immunotherapy treatments that activate immune cells to target cancer cells. The exact mechanisms involve cytokine release and potential direct neurotoxic effects.

Risk Factors

• Receipt of immunotherapy, especially CAR T-cell therapy or other immune effector cell treatments
• Underlying cancer type and disease burden
• Prior history of neurologic conditions or central nervous system involvement
• Concomitant use of other medications that may affect neurologic function

Symptoms

• Severe altered mental status or coma
• Profound aphasia (difficulty speaking or understanding language)
• Persistent seizures
• Significant ataxia (loss of coordination)
• Respiratory failure requiring mechanical ventilation
• Autonomic dysfunction

Diagnosis

Diagnosis is based on clinical evaluation of neurologic symptoms, including assessment of mental status, language function, motor activity, and autonomic signs. Grading follows standardized criteria (e.g., ASTCT consensus) to determine severity. Laboratory tests and imaging may be used to rule out other causes, but clinical presentation is primary.

Treatment Options

Treatment focuses on managing symptoms and supporting vital functions. Interventions may include corticosteroids, antiseizure medications, and intensive care support. Dose adjustments or temporary discontinuation of immunotherapy may be necessary. Management is tailored to the severity of neurologic impairment.

Prognosis and Follow-Up

Prognosis depends on the speed and effectiveness of treatment. Grade 5 ICANS carries a higher risk of long-term neurologic sequelae or mortality. Close monitoring in a specialized care setting is essential. Follow-up includes regular neurologic assessments to evaluate recovery and address any persistent deficits.

Complications

• Permanent neurologic damage
• Prolonged coma or cognitive impairment
• Respiratory failure
• Multi-organ dysfunction
• Increased risk of infection due to immunosuppressive treatments

Lifestyle & Prevention

Prevention is limited to careful patient selection and monitoring during immunotherapy. Patients should avoid activities requiring coordination or alertness if symptoms develop. Prompt reporting of new or worsening neurologic symptoms is critical.

When to Seek Professional Help

Seek immediate medical attention for symptoms such as severe confusion, difficulty speaking, seizures, or respiratory distress. These may indicate life-threatening ICANS requiring urgent intervention.

Tips for Medical Coders

Code G92.05 is used for immune effector cell-associated neurotoxicity syndrome of grade 5 severity. Documentation should specify the grade and clinical findings to support the diagnosis. Ensure alignment with the grading system used in the patient’s care (e.g., ASTCT criteria) and include details of neurologic symptoms and interventions.